Morgan Stanley Trims Catalent (NYSE:CTLT) Target Price to $50.00

Catalent (NYSE:CTLT – Get Rating) had its price objective lowered by Morgan Stanley from $85.00 to $50.00 in a research report released on Monday, The Fly reports.

Several other equities research analysts have also weighed in on the stock. StockNews.com initiated coverage on shares of Catalent in a report on Thursday, May 18th. They issued a sell rating on the stock. Robert W. Baird cut their target price on shares of Catalent from $53.00 to $35.00 in a report on Monday. Deutsche Bank Aktiengesellschaft increased their target price on shares of Catalent from $29.00 to $37.00 in a report on Monday. William Blair lowered shares of Catalent from an outperform rating to a market perform rating in a report on Friday, April 14th. Finally, Royal Bank of Canada dropped their price objective on shares of Catalent from $58.00 to $41.00 in a report on Monday, May 8th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, Catalent presently has a consensus rating of Hold and an average price target of $67.55.

Catalent Trading Down 1.5 %

CTLT opened at $36.88 on Monday. The firm’s fifty day moving average is $50.54 and its two-hundred day moving average is $52.80. The company has a debt-to-equity ratio of 0.86, a quick ratio of 1.38 and a current ratio of 1.91. The firm has a market cap of $6.64 billion, a PE ratio of 16.32, a price-to-earnings-growth ratio of 5.42 and a beta of 1.17. Catalent has a twelve month low of $31.45 and a twelve month high of $115.33.

Insider Activity at Catalent

In related news, SVP Mario Gargiulo sold 678 shares of the firm’s stock in a transaction on Monday, May 1st. The shares were sold at an average price of $49.86, for a total value of $33,805.08. Following the completion of the transaction, the senior vice president now owns 5,676 shares of the company’s stock, valued at $283,005.36. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, SVP Mario Gargiulo sold 678 shares of Catalent stock in a transaction dated Monday, May 1st. The shares were sold at an average price of $49.86, for a total value of $33,805.08. Following the completion of the transaction, the senior vice president now owns 5,676 shares of the company’s stock, valued at approximately $283,005.36. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Manja Boerman sold 1,446 shares of Catalent stock in a transaction dated Monday, May 1st. The shares were sold at an average price of $49.86, for a total transaction of $72,097.56. Following the completion of the transaction, the insider now directly owns 14,414 shares of the company’s stock, valued at approximately $718,682.04. The disclosure for this sale can be found here. 0.58% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Itau Unibanco Holding S.A. grew its position in shares of Catalent by 372.7% in the 3rd quarter. Itau Unibanco Holding S.A. now owns 3,134 shares of the company’s stock valued at $227,000 after acquiring an additional 2,471 shares during the period. Empirical Finance LLC boosted its holdings in shares of Catalent by 25.0% during the 3rd quarter. Empirical Finance LLC now owns 3,644 shares of the company’s stock worth $264,000 after buying an additional 728 shares during the period. Inspire Investing LLC boosted its holdings in shares of Catalent by 12.1% during the 4th quarter. Inspire Investing LLC now owns 25,647 shares of the company’s stock worth $1,154,000 after buying an additional 2,775 shares during the period. Asset Management One Co. Ltd. boosted its holdings in shares of Catalent by 1.3% during the 3rd quarter. Asset Management One Co. Ltd. now owns 74,710 shares of the company’s stock worth $5,406,000 after buying an additional 952 shares during the period. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Catalent by 313.9% during the 3rd quarter. Tower Research Capital LLC TRC now owns 49,717 shares of the company’s stock worth $3,597,000 after buying an additional 37,706 shares during the period. Institutional investors own 99.38% of the company’s stock.

Catalent Company Profile

(Get Rating)

Catalent, Inc is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services.